Psoriasis patients utilizing secukinumab, ixekizumab, or brodalumab – comparisons to prior biologic medication adherence levels, reasons for switching, and reported changes in disease symptoms
Crossref DOI link: https://doi.org/10.1080/21556660.2019.1658298
Published Online: 2019-09-06
Published Print: 2019-09-03
Update policy: https://doi.org/10.1080/tandf_crossmark_01
Baiano, Renee
Staskon, Francis
Miller, Rick
Version of Record valid from 2019-09-03
Peer Review Statement: The publishing and review policy for this title is described in its Aims & Scope.
Aim & Scope: http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ijda20
Publication History
Published: 2019-09-06
